Bone Biologics (NASDAQ:BBLG) Stock Price Up 1.4% – Should You Buy?

Bone Biologics Corp. (NASDAQ:BBLG)’s share price rose 1.4% on Tuesday . The stock traded as high as $1.3950 and last traded at $1.40. Approximately 4,281 shares changed hands during mid-day trading, a decline of 63% from the average daily volume of 11,622 shares. The stock had previously closed at $1.38.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bone Biologics in a report on Friday, March 27th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.

Bone Biologics Stock Up 1.4%

The firm’s 50-day moving average is $1.22 and its 200-day moving average is $1.62. The company has a market capitalization of $2.52 million, a PE ratio of -0.37 and a beta of 0.72.

Bone Biologics (NASDAQ:BBLG) last announced its earnings results on Monday, March 2nd. The company reported ($0.34) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.34). As a group, equities research analysts predict that Bone Biologics Corp. will post -1.93 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Bone Biologics stock. DRW Securities LLC increased its stake in Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 23,576 shares of the company’s stock after acquiring an additional 12,549 shares during the period. DRW Securities LLC owned about 1.31% of Bone Biologics worth $34,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 34.30% of the company’s stock.

Bone Biologics Company Profile

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.